v3.25.4
Business Combinations - Additional Information (Detail) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Nov. 12, 2025
Dec. 19, 2024
Dec. 31, 2025
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Business Combination [Line Items]              
Net revenues         $ 115,021,000 $ 185,827,000 $ 405,472,000
Net (loss) income         (68,731,000) $ (19,500,000) $ 53,655,000
BioMedomics, Inc              
Business Combination [Line Items]              
Contingent consideration, liability, value, high $ 5,000,000.0            
Estimated fair value of contingent consideration 233,000            
Contingent consideration, liability, value, Low $ 0            
Acquisition-related costs         $ 500,000    
Net revenues     $ 100,000        
Net (loss) income     $ 1,100        
BioMedomics, Inc | Technology-Based Intangible Assets              
Business Combination [Line Items]              
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life 10 years            
BioMedomics, Inc | Milestone Payments              
Business Combination [Line Items]              
Estimated fair value of contingent consideration $ 300,000            
Sherlock Biosciences              
Business Combination [Line Items]              
Contingent consideration, liability, value, high   $ 20,000,000.0          
Estimated fair value of contingent consideration   22,910,000          
Contingent consideration, liability, value, Low   0          
Fair value of the royalty fee acquisition-related contingent consideration   7,000,000          
Acquisition-related costs       $ 1,000,000.0      
Sherlock Biosciences | Milestone Payments              
Business Combination [Line Items]              
Estimated fair value of contingent consideration   $ 15,910,000